Objective To develop new classification criteria for systemic lupus erythematosus (SLE)
jointly supported by the European League Against Rheumatism (EULAR) and the American …

antibodies concomitant with larger atherosclerotic lesions that contained abundant CD4
cells. OxLDL is the type of LDL that is more likely to undergo uptake by macrophages, which …

Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers
of, antiphospholipid syndrome (APS). Although the presence of aPL is a necessary pre …

New clinical, laboratory and experimental insights, since the 1999 publication of the
Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been …

Objective To analyze the clinical and immunologic manifestations of antiphospholipid
syndrome (APS) in a large cohort of patients and to define patterns of disease expression …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

Objectives Develop recommendations for women9s health issues and family planning in
systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). Methods …

Objectives To assess the prevalence of the main causes of morbi-mortality in the
antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the …

The impact of autoimmune diseases is growing from both a clinical and a laboratory point of
view. Diagnostic assays are now being transferred from dedicated specialised laboratories …